Assenagon Asset Management S.A. Immuno Gen, Inc. Transaction History

Assenagon Asset Management S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 01, 2021	SELL	$3.7 - $7.66 $18.5 Million - $38.2 Million	-4,987,334 Closed	0 $0
Q3 2020 Oct 07, 2020	BUY	$3.45 - $4.89 $16.6 Million - $23.5 Million	4,811,013 Added 2728.55%	4,987,334 $18 Million
Q2 2020 Jul 21, 2020	BUY	$3.32 - $5.34 $585,385 - $941,554	176,321 New	176,321 $811,000
Q3 2019 Oct 16, 2019	SELL	$2.22 - $3.39 $262,661 - $401,091	-118,316 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$1.8 - $3.3 $212,968 - $390,442	118,316 New	118,316 $257,000
Q4 2018 Jan 23, 2019	SELL	$3.94 - $9.7 $240,781 - $592,786	-61,112 Closed	0 $0
Q3 2018 Oct 29, 2018	BUY	$8.6 - $11.26 $525,563 - $688,121	61,112 New	61,112 $579,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.